# NeoGenomics, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/NeoGenomics, Inc).

## Overview

NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer. It operates a network of cancer-focused laboratories in the United States and the United Kingdom and also serves pharmaceutical customers with clinical trial testing, biomarker analysis, and oncology data solutions.

## Products & services

• Clinical cancer testing
• Molecular and NGS testing
• MRD testing
• Pathology interpretation and consultative services
• Clinical trials and research support services
• Oncology data solutions

- **Clinical oncology testing** (55%) — Diagnostic laboratory testing used by physicians to detect, classify, and monitor cancer.
- **Molecular and NGS testing** (20%) — Next-generation sequencing and molecular assays used for therapy selection and disease characterization.
- **MRD testing** (10%) — Minimal residual disease testing used to detect very low levels of cancer after treatment.
- **Professional interpretation and consultative services** (7%) — Physician and molecular expert review of laboratory results, including second-opinion pathology.
- **Pharmaceutical development services** (5%) — Laboratory testing, biomarker analysis, and study support for sponsor-led clinical research.
- **Oncology data solutions** (3%) — Licensing of de-identified oncology data to pharma and biotech customers for research and targeting.

- Clinical cancer testing
- Molecular and NGS testing
- MRD testing
- Pathology interpretation and consultative services
- Clinical trials and research support services
- Oncology data solutions

## Customers

NeoGenomics sells primarily to healthcare providers that need specialized cancer testing and expert interpretation, including community oncology practices, hospitals, pathology labs, reference labs, and academic centers. It also serves pharmaceutical and biotech sponsors that need biomarker testing, sample analysis, and data support for oncology drug development and clinical trials. The company’s value proposition is speed, breadth of oncology test menu, and consultative support for complex cases.

- **Community oncology practices** (primary) — Buy routine and advanced cancer tests, MRD assays, and consultative support to manage patients locally.
- **Hospitals and hospital pathology labs** (primary) — Use NeoGenomics for specialized reference testing, complex case review, and overflow capacity.
- **Pathology and reference laboratories** (secondary) — Send difficult specimens for advanced molecular testing and expert interpretation.
- **Academic medical centers** (secondary) — Buy specialized oncology diagnostics for complex cases, research, and precision medicine programs.
- **Pharmaceutical and biotech sponsors** (secondary) — Purchase lab services, biomarker analysis, and oncology data for clinical trials and drug development.

- Community oncology practices buying broad cancer test menus and fast turnaround
- Hospital pathology labs needing specialized reference testing and second opinions
- Reference labs and academic centers outsourcing complex oncology cases
- Pharmaceutical and biotech sponsors needing biomarker and trial support
- Clinicians seeking expert pathology interpretation for difficult diagnoses

## Geography

NeoGenomics operates mainly in the United States, where most testing, sales, and customer relationships are concentrated. It also has a laboratory presence in Cambridge, United Kingdom, and receives some samples and data from outside the U.S., creating limited but real international compliance exposure. Geography matters because the business depends on specimen logistics, local lab capacity, and healthcare privacy rules across jurisdictions.

- Primary operations and revenue are in the United States
- Laboratories operate in Florida, California, North Carolina, New Jersey, and Texas
- Full-service sample-processing lab in Cambridge, United Kingdom
- Some international samples and employee data create GDPR/privacy exposure
- U.S. lab network supports specimen logistics and turnaround times

## Strategy

NeoGenomics is focused on expanding share in oncology diagnostics through new tests, especially therapy selection and MRD, while improving the customer experience and operational efficiency. The company is also pushing deeper into community oncology and using partnerships, sales coverage, and data-driven services to broaden its reach. Its strategy combines product innovation with service differentiation to defend pricing and win more complex cases.

- **Launch next-generation precision diagnostic tests** (short-term) — New therapy-selection and MRD assays support higher-value testing and strengthen the oncology menu.
- **Expand community oncology presence** (medium-term) — Community oncology is a key growth channel where broad menus and service quality can win share.
- **Optimize customer experience and operations** (short-term) — Automation and platform upgrades can improve turnaround times, margins, and retention.
- **Grow pharma development and data solutions** (medium-term) — Sponsor services and data licensing diversify revenue beyond routine clinical testing.

- Launch new therapy-selection and MRD tests
- Expand in community oncology and hospital channels
- Improve turnaround time and customer experience
- Use partnerships to widen market access
- Invest in automation, process improvement, and platform upgrades
- Grow pharma services and oncology data solutions

## Risks

NeoGenomics faces execution risk from rapid scientific change, capacity constraints, and the need to keep launching relevant tests in a competitive market. Its business is also exposed to reimbursement pressure, regulatory scrutiny in healthcare referrals and privacy, and operational disruption from cyberattacks or lab system failures. Goodwill and intangible asset impairment is another meaningful risk because acquisitions have created large balance-sheet estimates tied to future performance.

- **Competition and price pressure** [high] — The company competes with large reference labs and CROs, which can pressure pricing and win rates.
- **Capacity constraints** [high] — If lab throughput or staffing cannot keep pace with demand, growth and service levels can suffer.
- **Technology obsolescence** [high] — The company must continually develop or license new testing technologies to stay relevant.
- **Cybersecurity and IT disruption** [high] — Lab operations depend on LIMS, CRM, and data systems; outages can halt testing and billing.
- **Regulatory and privacy compliance** [medium] — Healthcare referral laws, HIPAA, and GDPR can create penalties and operational restrictions.
- **Goodwill and intangible asset impairment** [high] — Acquisition-related assets depend on future cash flows and can be written down if assumptions weaken.

- Competition and price pressure can reduce test pricing and margins
- Capacity constraints can limit growth and delay turnaround times
- Rapid technology change can make the test menu obsolete
- Cyberattacks or IT outages could disrupt lab operations and billing
- Healthcare referral and privacy laws create compliance risk
- Goodwill and intangible assets may be impaired if performance weakens

## Accounting

Revenue recognition and accounts receivable are key judgment areas because the company bills a mix of payers, including Medicare, insurers, and clients, with different collection patterns and reimbursement outcomes. Goodwill and intangible asset impairment is also important because acquisitions have created material non-cash assets and the company recorded impairment charges in 2025. Investors should also watch stock-based compensation, acquisition and integration costs, and amortization, which can materially affect reported earnings versus operating cash generation.

- **Revenue recognition and accounts receivable** — Can affect reported revenue, bad debt, and cash conversion
- **Goodwill and intangible impairment** — Can create large non-cash charges to earnings
- **Stock-based compensation** — Reduces reported profit without immediate cash outflow
- **Acquisition and integration costs** — Affects adjusted EBITDA and GAAP margin comparisons
- **Amortization of acquired intangibles** — Reduces operating income and net income

- Revenue recognition depends on payer mix and reimbursement outcomes
- Accounts receivable collectability affects reported revenue quality
- Goodwill and intangibles are subject to impairment testing
- Acquisition and integration costs can distort comparability
- Stock-based compensation and amortization affect earnings but not cash

---

*Last updated: 2026-04-28T20:28:24.054526+00:00*